EIGR Eiger BioPharmaceuticals Inc.

$10.3 -7.62%

39,216 Shares Traded
71,145 Average Volume (last 30 days)

as of April 19, 2018 EST IEX Real-Time Price

Free Newsletter Sign Up

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $246.08 thousand
If Intiated on the First, Shorts Have Realized a Year to Date Return of:26.69%
If Intiated One Month Ago, Shorts Have Realized a Return of:-10.75%
If Initiated Five Days ago, Shorts Have Realized a Return of:5.07%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points.

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bullish
50 Day Moving Average Indicator Bullish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 2.8%
Short Interest289.51 thousand
Float10.33 million
Short Ratio4.6
Market Cap$108.42 million
Market Maker ActivityDaily Short Volume

News

04-17-2018
Eiger's lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2% (SeekingAlpha)
04-17-2018
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress(TM) 2018 (PR Newswire)
04-09-2018
Biotech Forum: The Week Ahead (SeekingAlpha)
04-02-2018
Eiger BioPharmaceuticals to Participate in Conferences in April (PR Newswire)
03-26-2018
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia (PR Newswire)
03-22-2018
Your Daily Pharma Scoop: Achaogen's Plazomicin, Eiger Provides Update On Llonafarnib, Eleven Biotherapeutics Obtains Funding (SeekingAlpha)
03-21-2018
FDA signs off on single registration trial for Eiger Bio's lonafarnib in HDV; shares up 3% premarket (SeekingAlpha)
03-21-2018
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program (PR Newswire)
03-12-2018
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
03-06-2018
Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March (PR Newswire)


Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 67.9%
Insider Percent1.8%

Earnings Stats

PE Ratio -2.11
Dividend Yield 0%
Peer EarningsEarnings Calendar

Technicals

200 Day Moving Average $10.28
50 Day Moving Average $9.5
52 Week High $16.2
52 Week Low $6.1



Data provided for free by IEX. Questions? Read the FAQ